查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1472282

抗体生产市场：按产品、製程和最终用户分类：2023-2032 年全球机会分析和产业预测

Antibody Production Market By Product, By Process, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 276 Pages | 商品交期: 2-3个工作天内

价格

2022年抗体生产市场价值为123亿美元，预计到2032年将达到294亿美元，2023年至2032年的复合年增长率为9.1%。抗体产生是指免疫系统的特殊细胞（称为 B 细胞）产生抗体以应对细菌、病毒和其他病原体等外来物质的存在的过程。抗体，也称为免疫球蛋白，是一种 Y 形蛋白质，特异性识别并结合抗原（病原体表面存在的特异性分子）。

抗体生产市场-IMG1

当 B 细胞遇到与其特异性受体相符的抗原时，抗体产生过程就开始了。这种遭遇会触发 B 细胞活化和增殖，从而产生大量相同的 B 细胞（称为克隆）。活化的 B 细胞随后分化为浆细胞，浆细胞是抗体生产工厂。浆细胞将大量抗体分泌到血液和其他体液中，在那里它们与病原体结合併中和病原体，或标记它们以被其他免疫细胞破坏。

推动抗体製造市场成长的因素包括需要标靶治疗的慢性疾病数量的增加、生物技术的进步提高了生产效率和可扩展性、对用于治疗和研究应用的单株抗体的需求不断增加以及基于抗体的研究和发展政府有支持措施来促进这一点。此外，由于研发投资的增加以及生技药品治疗方法的采用增加，生物製药行业正在经历快速成长。抗体占生物製药的大部分，正在推动对抗体製造技术和服务的需求。

此外，旨在促进生物技术研究和开发的政府倡议以及对生物製药公司和学术机构的财政支持正在推动抗体生产市场的创新和成长。官民合作关係和津贴计画也有助于扩大抗体相关研究和商业化。例如，美国国立卫生研究院 (NIH) 计划在 2023 年推出抗体生产计划，美国研究建立和维持免疫反应的机制，包括广泛中和 HIV 抗体以预防 HIV 感染。因此，政府加大抗体研究和商业化倡议将进一步推动市场成长。此外，单株抗体（mAb）由于其高特异性和有效性而在各个治疗领域中获得了广泛接受。核准的单株抗体医药品数量的增加以及在肿瘤学、免疫学和其他领域的应用不断扩大正在推动对抗体生产和试剂的需求。

然而，与抗体开发和生产相关的高成本是抗体生产市场成长的主要限制。抗体开发需要一系列复杂且资源集中的步骤，包括抗原选择、融合瘤和噬菌体展示库生成、抗体筛检和优化。这些过程需要专业知识、精密设备和广泛的实验室资源，增加了开发成本。此外，治疗性抗体的生产涉及大量的细胞培养、精製、配製和品管步骤，所有这些都会导致更高的生产成本并可能抑制市场成长。另一方面，生物製药行业的成长和研发投资的增加为市场成长带来了机会。

抗体生产市场按产品、製程、最终用户和地区细分。依产品划分，市场分为设备和消耗品。设备部分进一步分为反应器、层析法系统和过滤系统。依流程划分，市场分为上游工程和下游流程。依最终用户划分，可分为製药/生技公司、CRO/CDMO 等。

相关人员的主要利益

  • 本报告定量分析了2022年至2032年抗体生产市场分析的细分市场、当前趋势、估计/趋势和动态，以识别一般抗体生产市场的机会。
  • 它提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析揭示了买家和供应商的潜力，帮助相关人员做出利润驱动的业务决策并加强供应商和买家网路。
  • 对抗体生产市场细分的详细分析有助于识别市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与企业定位有助于基准化分析，并提供对市场参与企业当前地位的清晰了解。
  • 该报告包括对区域和全球抗体生产市场趋势、主要企业、细分市场、应用细分和市场成长策略的分析。

该报告可以客製化（可能会产生额外的费用和时间，因此请联络您的销售负责人以了解详细资讯）。

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 关键投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章 抗体生产市场：副产品

  • 概述
  • 装置
    • 设备市场：依产品分类
  • 消耗品

第五章抗体製造市场：依製程分类

  • 概述
  • 上游工程
  • 下游工艺

第六章 抗体製造市场：依最终用户分类

  • 概述
  • 製药和生物技术公司
  • CRO 和 CDMO
  • 其他的

第七章 抗体製造市场 抗体製造市场：依地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲
    • 巴西
    • 哥伦比亚
    • 阿根廷
    • 其他拉丁美洲
  • 中东/非洲
    • Gcc
    • 南非
    • 北非
    • 其他的

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第九章 公司简介

  • Thermo Fisher Scientific Inc.
  • Sartorius AG
  • Cellabcdmo
  • Agilent Technologies, Inc.
  • Genetix Biotech Asia Pvt. Ltd.
  • Cell Culture Company
  • Bio-Rad Laboratories, Inc.
  • TECNIC
  • Merck KGaA
  • Danaher Corporation
Product Code: A03233

The antibody production market was valued at $12.3 billion in 2022 and is projected to reach $29.4 billion by 2032, registering a CAGR of 9.1% from 2023 to 2032. Antibody production refers to the process by which specialized cells in the immune system, called B cells, produce antibodies in response to the presence of foreign substances, such as bacteria, viruses, or other pathogens. Antibodies, also known as immunoglobulins, are Y-shaped proteins that specifically recognize and bind to antigens, which are unique molecules present on the surface of pathogens.

Antibody Production Market - IMG1

The process of antibody production begins when a B cell encounters an antigen that matches its specific receptor. This encounter triggers the activation and proliferation of the B cell, leading to the production of a large number of identical B cells, known as a clone. These activated B cells then differentiate into plasma cells, which are antibody-producing factories. Plasma cells secrete large quantities of antibodies into the bloodstream and other bodily fluids, where they can bind to and neutralize pathogens or mark them for destruction by other immune cells.

Factors driving the growth of the antibody production market include increase in prevalence of chronic diseases necessitating targeted therapies, advancements in biotechnology enhancing production efficiency and scalability, rising demand for monoclonal antibodies across therapeutic and research applications, and supportive government initiatives fostering research and development in antibody-based therapeutics. In addition, the biopharmaceutical industry is experiencing rapid growth due to increase in investments in research and development, as well as the rise in adoption of biologics-based therapies. Antibodies represent a significant portion of biopharmaceuticals, driving the demand for antibody production technologies and services.

Furthermore, government initiatives aimed at promoting biotechnology research and development, as well as funding support for biopharmaceutical companies and academic institutions, are fostering innovation and growth in the antibody production market. Public-private partnerships and grant programs are also contributing to the expansion of antibody-related research and commercialization efforts. For instance, in 2023, government initiatives for antibody production include the National Institutes of Health (NIH) supporting research to define mechanisms for establishing and maintaining immune responses, such as broadly neutralizing HIV antibodies to protect against HIV acquisition. Thus, rise in government initiatives for research and commercialization of antibodies further propels the market growth. Moreover, monoclonal antibodies (mAbs) have gained widespread acceptance in various therapeutic areas due to their high specificity and efficacy. The increasing number of approved monoclonal antibody drugs and their expanding applications in oncology, immunology, and other fields are driving the demand for antibody production and reagents.

However, the high costs associated with the development and production of antibodies present a significant restraint on the growth of the antibody production market. Antibody development involves a series of complex and resource-intensive processes, including antigen selection, hybridoma or phage display library generation, antibody screening, and optimization. These processes require specialized expertise, sophisticated equipment, and extensive laboratory resources, driving up development costs. Additionally, the production of therapeutic antibodies involves large-scale cell culture, purification, formulation, and quality control steps, all of which contribute to high production costs which may restrain market growth. On the other hand, the growing biopharmaceutical industry, coupled with increase in investments in research and development, presents opportunity to market growth.

The antibody production market is segmented on the basis of product, process, end user and region. By product, the market is bifurcated into instruments and consumables. The instruments segment is further categorized into bioreactors, chromatography systems, and filtration systems. By process, the market is divided into upstream processing and downstream processing. As per end user, it is segregated into pharmaceutical and biotechnology companies, CROs and CDMOs, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA). Major key players that operate in the antibody production market are Thermo Fisher Scientific Inc., Sartorius AG, Cellabcdmo, Agilent, Genetix Biotech Asia Pvt. Ltd., Cell Culture Company, Bio-Rad Laboratories, Inc, TECNIC, Merck KGaA, and Danaher Corporation. Key players have adopted acquisition as key developmental strategies to improve the product portfolio of the antibody production market.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antibody production market analysis from 2022 to 2032 to identify the prevailing antibody production market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antibody production market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antibody production market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By End User

  • Pharmaceutical and Biotechnology Companies
  • CROs and CDMOs
  • Others

By Product

  • Instruments
    • Type
    • Bioreactors
    • Chromatography Systems
    • Filtration Systems
  • Consumables

By Process

  • Upstream Processing
  • Downstream Processing

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Thermo Fisher Scientific Inc.
    • Sartorius AG
    • Cellabcdmo
    • Agilent Technologies, Inc.
    • Genetix Biotech Asia Pvt. Ltd.
    • Cell Culture Company
    • Bio-Rad Laboratories, Inc.
    • TECNIC
    • Merck KGaA
    • Danaher Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ANTIBODY PRODUCTION MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Instruments
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Instruments Antibody Production Market by Type
  • 4.3. Consumables
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: ANTIBODY PRODUCTION MARKET, BY PROCESS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Upstream Processing
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Downstream Processing
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: ANTIBODY PRODUCTION MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Pharmaceutical and Biotechnology Companies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. CROs and CDMOs
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Others
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ANTIBODY PRODUCTION MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Product
    • 7.2.3. Market size and forecast, by Process
    • 7.2.4. Market size and forecast, by End User
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Product
      • 7.2.5.1.2. Market size and forecast, by Process
      • 7.2.5.1.3. Market size and forecast, by End User
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Product
      • 7.2.5.2.2. Market size and forecast, by Process
      • 7.2.5.2.3. Market size and forecast, by End User
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Product
      • 7.2.5.3.2. Market size and forecast, by Process
      • 7.2.5.3.3. Market size and forecast, by End User
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Product
    • 7.3.3. Market size and forecast, by Process
    • 7.3.4. Market size and forecast, by End User
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Product
      • 7.3.5.1.2. Market size and forecast, by Process
      • 7.3.5.1.3. Market size and forecast, by End User
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Product
      • 7.3.5.2.2. Market size and forecast, by Process
      • 7.3.5.2.3. Market size and forecast, by End User
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Product
      • 7.3.5.3.2. Market size and forecast, by Process
      • 7.3.5.3.3. Market size and forecast, by End User
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Product
      • 7.3.5.4.2. Market size and forecast, by Process
      • 7.3.5.4.3. Market size and forecast, by End User
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Product
      • 7.3.5.5.2. Market size and forecast, by Process
      • 7.3.5.5.3. Market size and forecast, by End User
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Product
      • 7.3.5.6.2. Market size and forecast, by Process
      • 7.3.5.6.3. Market size and forecast, by End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Product
    • 7.4.3. Market size and forecast, by Process
    • 7.4.4. Market size and forecast, by End User
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Product
      • 7.4.5.1.2. Market size and forecast, by Process
      • 7.4.5.1.3. Market size and forecast, by End User
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Product
      • 7.4.5.2.2. Market size and forecast, by Process
      • 7.4.5.2.3. Market size and forecast, by End User
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Product
      • 7.4.5.3.2. Market size and forecast, by Process
      • 7.4.5.3.3. Market size and forecast, by End User
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Product
      • 7.4.5.4.2. Market size and forecast, by Process
      • 7.4.5.4.3. Market size and forecast, by End User
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Product
      • 7.4.5.5.2. Market size and forecast, by Process
      • 7.4.5.5.3. Market size and forecast, by End User
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Product
      • 7.4.5.6.2. Market size and forecast, by Process
      • 7.4.5.6.3. Market size and forecast, by End User
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Product
    • 7.5.3. Market size and forecast, by Process
    • 7.5.4. Market size and forecast, by End User
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Product
      • 7.5.5.1.2. Market size and forecast, by Process
      • 7.5.5.1.3. Market size and forecast, by End User
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Product
      • 7.5.5.2.2. Market size and forecast, by Process
      • 7.5.5.2.3. Market size and forecast, by End User
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Product
      • 7.5.5.3.2. Market size and forecast, by Process
      • 7.5.5.3.3. Market size and forecast, by End User
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Product
      • 7.5.5.4.2. Market size and forecast, by Process
      • 7.5.5.4.3. Market size and forecast, by End User
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Product
    • 7.6.3. Market size and forecast, by Process
    • 7.6.4. Market size and forecast, by End User
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Product
      • 7.6.5.1.2. Market size and forecast, by Process
      • 7.6.5.1.3. Market size and forecast, by End User
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Product
      • 7.6.5.2.2. Market size and forecast, by Process
      • 7.6.5.2.3. Market size and forecast, by End User
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Product
      • 7.6.5.3.2. Market size and forecast, by Process
      • 7.6.5.3.3. Market size and forecast, by End User
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Product
      • 7.6.5.4.2. Market size and forecast, by Process
      • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Thermo Fisher Scientific Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Sartorius AG
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Cellabcdmo
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Agilent Technologies, Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Genetix Biotech Asia Pvt. Ltd.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Cell Culture Company
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Bio-Rad Laboratories, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. TECNIC
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Merck KGaA
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Danaher Corporation
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 02. ANTIBODY PRODUCTION MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. GLOBAL INSTRUMENTS ANTIBODY PRODUCTION MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 04. ANTIBODY PRODUCTION MARKET FOR CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 06. ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 09. ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. ANTIBODY PRODUCTION MARKET FOR CROS AND CDMOS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. ANTIBODY PRODUCTION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. ANTIBODY PRODUCTION MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 18. U.S. ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 20. CANADA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 21. CANADA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 36. UK ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 37. UK ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 38. UK ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. ITALY ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 40. ITALY ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 41. ITALY ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. JAPAN ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 55. CHINA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 56. CHINA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 58. INDIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 59. INDIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 60. INDIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 77. COLOMBIA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 80. ARGENTINA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 86. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA ANTIBODY PRODUCTION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 90. GCC ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 91. GCC ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 92. GCC ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 96. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 99. REST OF MEA ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MEA ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MEA ANTIBODY PRODUCTION MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 102. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 103. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 104. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
  • TABLE 105. THERMO FISHER SCIENTIFIC INC.: SERVICE SEGMENTS
  • TABLE 106. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 107. THERMO FISHER SCIENTIFIC INC.: KEY STRATERGIES
  • TABLE 108. SARTORIUS AG: KEY EXECUTIVES
  • TABLE 109. SARTORIUS AG: COMPANY SNAPSHOT
  • TABLE 110. SARTORIUS AG: PRODUCT SEGMENTS
  • TABLE 111. SARTORIUS AG: SERVICE SEGMENTS
  • TABLE 112. SARTORIUS AG: PRODUCT PORTFOLIO
  • TABLE 113. SARTORIUS AG: KEY STRATERGIES
  • TABLE 114. CELLABCDMO: KEY EXECUTIVES
  • TABLE 115. CELLABCDMO: COMPANY SNAPSHOT
  • TABLE 116. CELLABCDMO: PRODUCT SEGMENTS
  • TABLE 117. CELLABCDMO: SERVICE SEGMENTS
  • TABLE 118. CELLABCDMO: PRODUCT PORTFOLIO
  • TABLE 119. CELLABCDMO: KEY STRATERGIES
  • TABLE 120. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 121. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 122. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
  • TABLE 123. AGILENT TECHNOLOGIES, INC.: SERVICE SEGMENTS
  • TABLE 124. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 125. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
  • TABLE 126. GENETIX BIOTECH ASIA PVT. LTD.: KEY EXECUTIVES
  • TABLE 127. GENETIX BIOTECH ASIA PVT. LTD.: COMPANY SNAPSHOT
  • TABLE 128. GENETIX BIOTECH ASIA PVT. LTD.: PRODUCT SEGMENTS
  • TABLE 129. GENETIX BIOTECH ASIA PVT. LTD.: SERVICE SEGMENTS
  • TABLE 130. GENETIX BIOTECH ASIA PVT. LTD.: PRODUCT PORTFOLIO
  • TABLE 131. GENETIX BIOTECH ASIA PVT. LTD.: KEY STRATERGIES
  • TABLE 132. CELL CULTURE COMPANY: KEY EXECUTIVES
  • TABLE 133. CELL CULTURE COMPANY: COMPANY SNAPSHOT
  • TABLE 134. CELL CULTURE COMPANY: PRODUCT SEGMENTS
  • TABLE 135. CELL CULTURE COMPANY: SERVICE SEGMENTS
  • TABLE 136. CELL CULTURE COMPANY: PRODUCT PORTFOLIO
  • TABLE 137. CELL CULTURE COMPANY: KEY STRATERGIES
  • TABLE 138. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
  • TABLE 139. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
  • TABLE 140. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
  • TABLE 141. BIO-RAD LABORATORIES, INC. : SERVICE SEGMENTS
  • TABLE 142. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
  • TABLE 143. BIO-RAD LABORATORIES, INC. : KEY STRATERGIES
  • TABLE 144. TECNIC: KEY EXECUTIVES
  • TABLE 145. TECNIC: COMPANY SNAPSHOT
  • TABLE 146. TECNIC: PRODUCT SEGMENTS
  • TABLE 147. TECNIC: SERVICE SEGMENTS
  • TABLE 148. TECNIC: PRODUCT PORTFOLIO
  • TABLE 149. TECNIC: KEY STRATERGIES
  • TABLE 150. MERCK KGAA: KEY EXECUTIVES
  • TABLE 151. MERCK KGAA: COMPANY SNAPSHOT
  • TABLE 152. MERCK KGAA: PRODUCT SEGMENTS
  • TABLE 153. MERCK KGAA: SERVICE SEGMENTS
  • TABLE 154. MERCK KGAA: PRODUCT PORTFOLIO
  • TABLE 155. MERCK KGAA: KEY STRATERGIES
  • TABLE 156. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 157. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 158. DANAHER CORPORATION: PRODUCT SEGMENTS
  • TABLE 159. DANAHER CORPORATION: SERVICE SEGMENTS
  • TABLE 160. DANAHER CORPORATION: PRODUCT PORTFOLIO
  • TABLE 161. DANAHER CORPORATION: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. ANTIBODY PRODUCTION MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF ANTIBODY PRODUCTION MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN ANTIBODY PRODUCTION MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN ANTIBODY PRODUCTION MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL ANTIBODY PRODUCTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. ANTIBODY PRODUCTION MARKET, BY PRODUCT, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR CONSUMABLES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. ANTIBODY PRODUCTION MARKET, BY PROCESS, 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR UPSTREAM PROCESSING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR DOWNSTREAM PROCESSING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. ANTIBODY PRODUCTION MARKET, BY END USER, 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR CROS AND CDMOS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ANTIBODY PRODUCTION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. ANTIBODY PRODUCTION MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 22. U.S. ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. GERMANY ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. FRANCE ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. UK ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. ITALY ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. SPAIN ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. JAPAN ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. CHINA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. INDIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. AUSTRALIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH KOREA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. COLOMBIA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. ARGENTINA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF LA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. GCC ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. SOUTH AFRICA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. NORTH AFRICA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF MEA ANTIBODY PRODUCTION MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49. COMPETITIVE DASHBOARD
  • FIGURE 50. COMPETITIVE HEATMAP: ANTIBODY PRODUCTION MARKET
  • FIGURE 51. TOP PLAYER POSITIONING, 2022